Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company raised its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 16.7% during the second quarter, Holdings Channel.com reports. The firm owned 13,964 shares of the company’s stock after purchasing an additional 1,994 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Stoke Therapeutics were worth $189,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Quest Partners LLC purchased a new stake in shares of Stoke Therapeutics in the 2nd quarter valued at approximately $29,000. Nisa Investment Advisors LLC lifted its position in shares of Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Stoke Therapeutics during the second quarter worth $123,000. State Board of Administration of Florida Retirement System purchased a new position in Stoke Therapeutics in the first quarter valued at $141,000. Finally, BNP Paribas Financial Markets increased its holdings in Stoke Therapeutics by 86.2% in the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after buying an additional 6,636 shares during the last quarter.

Stoke Therapeutics Stock Down 2.0 %

Shares of Stoke Therapeutics stock opened at $13.00 on Friday. The business has a 50-day moving average price of $13.69 and a 200 day moving average price of $13.70. Stoke Therapeutics, Inc. has a fifty-two week low of $3.35 and a fifty-two week high of $17.58. The firm has a market cap of $677.57 million, a P/E ratio of -5.39 and a beta of 0.97.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The company had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.33 million. As a group, equities research analysts anticipate that Stoke Therapeutics, Inc. will post -2.11 earnings per share for the current year.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the firm’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the transaction, the insider now owns 8,906,181 shares of the company’s stock, valued at approximately $125,131,843.05. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Leerink Partners began coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Thursday, August 8th. Wedbush reissued an “outperform” rating and issued a $17.00 price target on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, September 11th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $20.83.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.